{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"10.5","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"60"}],"units":"Participants"}],"description":"NRM (Non relapse mortality) - death not attributed to the primary cancer.","dispersionType":"95% Confidence Interval","groups":[{"description":"Conditioning with Treosulfan (12 or 14 g/m2, IV for 5 days) and Fludarabine (30 mg/m2, IV for 5 days) followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies","id":"OG000","title":"Treosulfan and Fludarabine Conditioning"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"200 days","title":"Incidence (Percent of Participants) With Nonrelapse Mortality (NRM) by Day 200 (Secondary Phase Only)","type":"PRIMARY","unitOfMeasure":"percent of participants"}